Four lines, one page, one comparison
Both molecules appear in both routes on the same catalogue page, each with a flat monthly figure. Choosing a tablet over an injection is therefore a subtraction a reader can do in their head rather than an enquiry, and the tablet is the cheaper option for each molecule.
That inversion is worth noting because it runs against the pattern. On most sellers here that publish both routes, the oral formulation costs more. A reader who has been avoiding tablets on the assumption they carry a premium should check this one.
The figure is stated to be the bill
The product page lists what is included: the physician consultation, supplies, shipping and ongoing support. That is a programme charge rather than a medication line item, and it is why no separate consultation fee is recorded here.
The site also publishes a postal address, a support telephone number and support hours, and names the operating company outright. Contactability of that kind is not a clinical credential, but it is a meaningful signal in a category where a brand with no company behind it is common.
The New Patient tag is unexplained
Every GLP-1 tile carries a New Patient label. Nothing on the page says whether the figure changes once a patient stops being new, and this review does not assume either way.
It is the one thing that would move this row substantially. A flat rate that quietly becomes something else after the first order is a different product from a flat rate, and the site does not close the question.
Sourcing is not disclosed
The compounding pharmacy is never named. The product pages describe the medication, the mechanism and the injection protocol in some detail, and then say nothing at all about who prepares it.
No individual prescribing clinician or medical director is named despite the physician-led framing, and no list of states served appears anywhere we read. Everything offered is compounded, with no brand-name route on the catalogue.
YOURx Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $159/moper month; the product page states the figure includes the physician consultation, supplies, shipping and ongoing support | September 2026source |
| Tirzepatide (compounded) | $179/moper month on the treatments catalogue, priced $20 above the semaglutide injection | September 2026source |
| Semaglutide (compounded-oral) | $139/moper month on the treatments catalogue — the cheapest of its four GLP-1 lines, and the only roster of four where the oral route costs less than the injection | September 2026source |
| Tirzepatide (compounded-oral) | $159/moper month on the treatments catalogue | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 283 providers reviewed here are paid partners today; the other 279 are not. See how this works.
See YOURx Health's current price →Good fit if
- Readers deciding between an injection and a tablet who want both priced on the same page.
- Patients drawn to an oral route, which is the cheaper option here for each molecule.
- Anyone who wants consultation, supplies, shipping and support stated as covered by one figure.
- Readers who value a published postal address, telephone number and named operating company.
Look elsewhere if
- Anyone who needs the compounding pharmacy named.
- Patients who want a named prescribing clinician or medical director.
- Readers who must confirm their state is served before starting.
- Anyone uneasy about a price tagged New Patient with no statement of what follows it.
How this review was verified
- Read the treatments catalogue and the semaglutide injection product page at their source URLs and logged all four figures with the date they were read.
- Mapped each figure to the product described immediately before it rather than to the nearest product name, and confirmed the mapping against the individual product page for the semaglutide injection.
- Took the inclusions from the product page verbatim and used them to decide that no separate consultation charge applies.
- Recorded the New Patient tag as an open question rather than assuming the figure does or does not change.
- Pulled all 3,677 rows of the FDA warning-letter table and filtered them locally with a known-positive and a nonsense-string control in the same run; no letter for the brand or the operating company.